JNJ completes Laminar acquisition for $400M upfront; cuts FY2023 adjusted EPS guidance by $0.17

JOHNSON & JOHNSON

Upfront payment of $400M (subject to adjustments) plus potential clinical/regulatory milestone payments.
Laminar's LAAX device uses rotational motion to eliminate left atrial appendage; FDA approved U.S. pivotal study starting in early 2024.
FY2023 adjusted operational EPS guidance revised to $9.85-$9.91; reported to $9.90-$9.96, reflecting $0.17 IPR&D charge.
Acquisition expected to reduce FY2024 EPS by approximately $0.15.
Biosense Webster (JNJ MedTech) will integrate Laminar; targets ~38M AFib patients worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.